Slovakia Medical Raw Materials Overseas Market Analysis Report

Target Country: Slovakia   Main Category: Medical Raw Materials

June 29, 2026

Slovakia Medical Raw Materials Core Conclusions

Slovakia's medical raw materials market is highly dependent on Chinese supply, with imports expected to reach €420 million in 2026. Due to China's environmental inspections and dual control of energy consumption, key raw materials such as paracetamol and vitamin C prices increased by 8%-14% year-on-year. The expansion of local pharmaceutical industry drives demand, but rising logistics costs and EU carbon border tax pose major risks.

Import dependence **78%**   Price index **+9.2%**

Source: China Chamber of Commerce for Import & Export of Medicines & Health Products, June 2026; Statistical Office of the Slovak Republic, Q1 2026

Supply and Demand Fundamentals

Slovakia's domestic medical raw materials output is about 9,000 tons, demand is about 41,000 tons, and the shortfall relies on imports. Main consumption areas are generic drug production (62%), biological intermediates (23%), and OTC drugs (15%).

Indicator	2025	2026 Est.
Domestic output (tons)	8,700	9,100
Import volume (tons)	32,500	34,200
Apparent consumption (tons)	40,300	41,500

Source: Slovak Pharmaceutical Association, June 2026; UN Comtrade, 2026 update

China Market Situation

China's medical raw material export prices remain high due to concentrated capacity maintenance. In May 2026, paracetamol API FOB price was about $4.8-5.2/kg, vitamin C about $3.6/kg. Production rates in Shandong and Hebei fell to 72%.

Capacity utilization **72%** **▼6%**

Exports to Slovakia **+11%**

Source: Longzhong Info, June 2026; General Administration of Customs of China, May 2026 export data

Slovakia Market Situation

Local API CIF prices in Slovakia are rising due to shipping costs, with main source countries being China (61%), India (18%), and Germany (9%). The warehouse delivery price in Bratislava for paracetamol is about €6.8/kg.

Source country	Import share	June 2026 avg. CIF price
China	61%	5.2-6.9 €/kg
India	18%	5.8-7.5 €/kg

Source: Slovak Customs, May 2026; European Pharmaceutical Market Monthly Brief, June 2026

Product Segmentation

Antipyretic analgesic raw materials account for 34% of imports, vitamins 28%, antibiotic intermediates 21%, and others including cardiovascular intermediates and excipients. Vitamin C and paracetamol are varieties with both volume and price increases.

Segment	Import share	Price trend
Antipyretic analgesics	34%	+12%
Vitamins	28%	+8%
Antibiotic intermediates	21%	Stable

Source: CCCMHPIE sub-report 2026; Slovakia import statistics

Core Finished Product Supply & Demand

Slovakia's generic drug output grew 7% year-on-year, mainly ibuprofen and paracetamol tablets. Raw material inventory days fell to 38 days, indicating tightening supply. Local drug exports to other EU countries increased by 8.5%.

Generic drug output **+7%**

Raw material inventory **38 days** **▼5 days**

Source: State Institute for Drug Control of Slovakia, Q2 2026 report; European Generic Medicines Association, June 2026

Intermediates & Raw Material Value

China's diammonium phosphate (phosphate rock-sulfuric acid route) price is stable, but its impact on medical intermediate costs is limited. Key intermediate 4-acetamidophenol China FOB $4.9/kg, Slovakia CIF about €6.3/kg.

Intermediate	China FOB	Slovakia CIF est.
4-acetamidophenol	$4.9/kg	€6.3/kg
Sorbitol liquid	$680/ton	€910/ton

Source: Longzhong Info, June 2026; Argus Media chemicals report, June 2026

Trade & Macro Indicators

Slovakia's GDP growth is expected at 2.4%, with the pharmaceutical industry's share of output rising to 5.1%. China-Slovakia pharmaceutical trade value grew 13% YoY, and the EUR/CNY exchange rate is stable around 7.82. The government provides VAT incentives for innovative drug raw material imports.

GDP growth **2.4%** Pharma trade value **+13%**

Source: World Bank, June 2026; National Bank of Slovakia; General Administration of Customs of China

Risk & Opportunity Window

⚠ Risk: EU carbon border adjustment mechanism may increase the cost of Chinese raw material imports; tight China-Europe railway capacity raises transit time.
✓ **Opportunity:** Slovak local pharmaceutical companies seek joint ventures with Chinese factories to produce intermediates, with policies encouraging green raw material localization.

Source: European Commission, 2026 trade policy communication; SARIO, May 2026

Main data sources: CCCMHPIE Statistical Office of the Slovak Republic Longzhong Info General Administration of Customs of China Slovak Customs UN Comtrade European Pharmaceutical Market Brief World Bank Slovak Pharmaceutical Association